Abstract:Background The treatment of dopamine agonists (DA) resistant prolactinomas remains a formidable challenge, as the mechanism of resistance is still unclear, and there are currently no viable alternative drug therapies available. This study seeks to investigate the mechanism of DA resistance in prolactinomas and identify new potentially effective drugs. Methods To explore the mechanism of DA resistance in prolactinomas, this study conducted transcriptome sequencing analysis on 27 cases of DA-resistant prolactinomas and 10 cases of sensitive prolactinomas. In addition, single-cell sequencing analysis was performed on 3 cases of DA-resistant prolactinomas and 3 cases of sensitive prolactinomas. Furthermore, to screen for potential therapeutic drugs, the study successfully established an organoids model for DA-resistant prolactinomas and screened 180 small molecule compounds using 8 organoids. The efficacy of the identified drugs was verified through various assays, including CCK-8, colony formation, CTG, and flow cytometry, and their mechanisms of action were confirmed through WB and IHC. The effectiveness of the identified drugs was evaluated both in vitro and in vivo. Results The results of transcriptome sequencing and single-cell sequencing analyses showed that DA resistance in prolactinomas is associated with the upregulation of the Focal Adhesion (FA) signaling pathway. Additionally, immunohistochemical validation revealed that FAK and Paxillin were significantly upregulated in DA-resistant prolactinomas. Screening of 180 small molecule compounds using 8 organoids identified Genistein as a potentially effective drug for DA-resistant prolactinomas. Experimental validation demonstrated that Genistein inhibited the proliferation of pituitary tumor cell lines and organoids and promoted apoptosis in pituitary tumor cells. Moreover, both the cell sequencing results and WB validation results of the drug-treated cells indicated that Genistein exerts its anti-tumor effect by inhibiting the FA pathway. In vivo, experiments also showed that Genistein can inhibit subcutaneous tumor formation. Conclusion DA resistance in prolactinomas is associated with upregulation of the Focal Adhesion (FA) signaling pathway, and Genistein can exert its anti-tumor effect by inhibiting the expression of the FA pathway.

Genomic characterization of human and rat prolactinomas.

Expression of Stem Cell Markers and Dopamine D2 Receptors in Human and Rat Prolactinomas

A diagnostic marker set for invasion, proliferation, and aggressiveness of prolactin pituitary tumors

Identification of Human Prolactinoma Related Genes by DNA Microarray.

Cross-species Comparison of Orthologous Gene Expression in Human Bladder Cancer and Carcinogen-Induced Rodent Models.

Somatic Activating ESR1 Mutation in an Aggressive Prolactinoma

Supplementary Table 1 from Concordant Effects of Aromatase Inhibitors on Gene Expression in ER<sup>+</sup> Rat and Human Mammary Cancers and Modulation of the Proteins Coded by These Genes

Prolactin Regulates Testicular Gene Expression and Cell Cycle Processes Predominantly via JAK2/STAT5 Pathway in the Male Rat

Correlation of Alternative Splicing of the D2 Dopamine Receptor Mrna and Estrogen Receptor Mrna in the Prolactinomas and Gonadotrope Tumors

Tumor expression of human growth hormone and human prolactin predict a worse survival outcome in patients with mammary or endometrial carcinoma.

Drug resistance mechanisms in dopamine agonist-resistant prolactin pituitary neuroendocrine tumors and exploration for new drugs

Network pharmacology analysis and molecular mechanism of paeoniflorin and its metabolite in prolactinoma cells

A Gene Expression Signature Predicts Chemopreventive Response of an EGFR Inhibitor in a Rat Mammary Cancer Model.

Microrna Expression Profile and Differentially-Expressed Genes in Prolactinomas Following Bromocriptine Treatment

Effect of prolactin on the population of epithelial cells from ventral prostate of intact and cyproterone acetate-treated peripubertal rats: stereological and immunohistochemical study

Gene Expression of Gonadotropin-Releasing Hormone and Its Receptor in Rat Pancreatic Cancer Cell Lines

DRD2 expression based on 18F-fallypride PET/MR predicts the dopamine agonist resistance of prolactinomas: A pilot study

The Prolactin Receptor Mediates Hoxa1-Stimulated Oncogenicity in Mammary Carcinoma Cells

Anti-EGFL7 antibodies inhibit rat prolactinoma MMQ cells proliferation and PRL secretion

Cebpd Suppresses Prolactin Expression and Prolactinoma Cell Proliferation

Poster #157 SPURIOUS SIGNAL DETECTION AND DELUSIONS OF REFERENCE IN FIRST-EPISODE SCHIZOPHRENIA